IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation

Immunological Reviews

Volumn 163, Issue , 1998, Pages 59-76

  Jefferis, Roy ^a   Lund, John ^a   Pound, John D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

CRYSTAL STRUCTURE; IMMUNOGLOBULIN STRUCTURE; LIGAND BINDING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; REVIEW; TOPOGRAPHY;

ANIMALS; BACTERIAL PROTEINS; BINDING SITES; CARBOHYDRATE CONFORMATION; CARRIER PROTEINS; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LIGANDS; MANNOSE-BINDING LECTINS; OLIGOSACCHARIDES; PROTEIN CONFORMATION; RECEPTORS, IGG; RHEUMATOID FACTOR;

EID: 0031868555     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01188.x     Document Type: Review

References (93)

1. Harris LJ, Larson SB, Hasel KW, McPherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 1997;36:1581-1597.
2. Silverton EW, Navia MA, Davies DR. Three-dimensional structure of an intact human immunoglobulin. Proc Natl Acad Sci USA 1977;74:5140-5144.
3. Guddat LW, Herron JN, Edmundson AB. Three-dimensional structure of a human immunoglobulin with a hinge deletion. Proc Natl Acad Sci USA 1993;90:4271-4275.
4. Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994;31:169-217.
5. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 1981;20:2361-2370.
6. Padlan EA. X-ray diffraction studies of antibody constant regions. In: Metzger H, ed. Fc receptors and the action of antibodies. Washington DC: American Society for Microbiology; 1990. p. 12-30.
7. Burton DR. Immunoglobulin G - functional sites. Mol Immunol 1985;22:161-206.
8. Burton DR, Woof JM. Human antibody effector function. Adv Immunol 1992;51:1-84.
9. Jefferis R. Structure/function relationships for the human IgG subclasses. In: Shakib F, ed. The human IgG subclasses: molecular analysis of structure, function and regulation. Oxford: Pergamon Press; 1990. p. 93-108.
10. Jefferis R, Kumararatne DS. Selective IgG subclass deficiency: quantification and clinical relevance. Clin Exp Immunol 1990;81:357-368.
11. Gregory L, et al. The solution conformations of the subclasses of human IgG deduced from sedimentation and small-angle x-ray-scattering studies. Mol Immunol 1987;24:821-829.
12. Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol 1997;159:3372-3382.
13. Guddat LW, Shan L, Anchin JM, Linthicum DS, Edmundson AB. Local and transmitted conformational changes on complexation of an anti-sweetener Fab. J Mol Biol 1994;236:247-274.
14. Chen FH, Arya SK, Rinfret A, Isenman DE, Shulman MJ, Painter RH. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for Cμ2, Cμ3, and Cμ4 domains in the regulation of the interaction of IgM with complement C1q. J Immunol 1997;159:3354-3363.
15. Marquart M, Deisenhofer J, Huber R, Palm W. Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 Å and 1.0 Å resolution. J Mol Biol 1980;141:369-391.
16. Brekke OH, Michaelsen TE, Sandlie R, Sandlie I. Activation of complement by an IgG molecule without a genetic hinge [retracted in Nature 1996;383:103]. Nature 1993;363:628.
17. Coloma MJ, Trinh KR, Wims LA, Morrison SL. The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J Immunol 1997;158:733-740.
18. Deisenhofer J, Colman PM, Huber R, Haupt H, Schwick G. Crystallographic structural studies of a human Fc fragment. I. An electron density map at 4 Å resolution and a partial model. Hoppe Seylers Z Physiol Chem 1976;357: 435-445.
19. Deisenhofer J, Colman PM, Epp O, Huber R. Crystallographic structural studies of a human Fc fragment. II. A complete model based on a Fourier map at 3.5 Å resolution. Hoppe Seylers Z Physiol Chem 1976;357: 1421-1434.
20. Lund J, et al. Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG. J Immunol 1991;147:2657-2662.
21. Sauer-Eriksson AE, Kleywegt GJ, Uhl M, Jones TA. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 1995;3:265-278.
22. Sohi MK, et al. Crystallization of a complex between the Fab fragment of a human immunoglobulin M (IgM) rheumatoid factor (RF-AN) and the Fc fragment of human IgG4. Immunology 1996;88:636-641.
23. Corper AL, et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997;4:374-381.
24. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994;372:379-383.
25. 1 and its low affinity receptor FcγRIII. Biochemistry 1995;34:13320-13327.
26. Rudd PM, Dwek RA. Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 1997;32: 1-100.
27. Jefferis R, et al. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J 1990;268:529-537.
28. Routier FH, et al. Quantitation of human IgG glycoforms isolated from rheumatoid sera: a critical evaluation of chromatographic methods. J Immunol Methods 1998 (In press).
29. Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcγRI and/or FcγRII receptors. Biochem J 1989;259:347-353.
30. Pound JD, Lund J, Jefferis R. Aglycosylated chimeric human IgG3 can trigger the human phagocyte respiratory burst. Mol Immunol 1993;30:233-241.
31. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcy receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 1996;157:4963-4969.
32. Lund J, Takahashi N, Pound JD, Goodall M, Nakagawa H, Jefferis R. Oligosaccharide protein interactions in IgG can modulate recognition by Fcy receptors. FASEB J 1995;9:115-119.
33. Jefferis R. Lund J. Glycosylation of antibody molecules: structural and functional significance. Chem Immunol 1997;65:111-128.
34. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotech 1997;15:26-32.
35. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Agalactosyl IgG activates complement via mannose-binding protein. Nat Med 1995;1:237-243.
36. Abadeh S, Church S, Dong S, Lund J, Goodall M, Jefferis R. Remodelling the oligosaccharide of human IgG antibodies: effects on biological activities. Biochem Soc Trans 1997;25:S661.
37. Bodman-Smith K, Sumar N, Sinclair H, Roitt I, Isenberg D, Young A. Agalactosyl IgG [Gal(0)] - an analysis of its clinical utility in the long term follow up of patients with rheumatoid arthritis. Br J Rheumatol 1996;35:1063-1066.
38. Jenkins N, Curling E. Glycosylation of recombinant proteins: problems and prospects. Enzyme Micro Technol 1995;16: 354-364.
39. Farooq M, Takahashi N, Arrol H, Drayson M, Jefferis R. Glycosylation of polydonal and paraprotein IgG in multiple myeloma. Glycoconj J 1997;14:489-492.
40. Sutton BJ, Phillips DC. The 3-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G. Biochem Soc Trans 1983;11:130-132.
41. Jefferis R, Lund J, Goodall M. Recognition sites on human IgG for Fcγ receptors - the role of glycosylation. Immunol Lett 1995;44:111-117.
42. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997;36:1370-1380.
43. Gilhespy-Muskett AM, Partridge J, Jefferis R, Homans SW. A novel C-13 isotopic labeling strategy for probing the structure and dynamics of glycan chains in situ on glycoproteins. Glycobiology 1994;4:485-489.
44. Matsuda H, et al. Proton nuclear magnetic resonance studies of the structure of the Fc fragment of human immunoglobulin G1 - comparisons of native and recombinant proteins. Mol Immunol 1990;27:571-579.
45. Lund J, Tanaka T, Takahashi N, Sarmay G, Arata Y, Jefferis R. A protein structural change in aglycosylated IgG3 correlates with loss of huFcγRI and huFcγRIII binding and/or activation. Mol Immunol 1990;27:1145-1153.
46. Tishchenko V, Lund J, Goodall M, Jefferis R. Differences in thermodynamic parameters for the co-operative structures within glycosylated and aglycosylated mouse IgG2b. In: Chowdhry B, Ladbury J, eds. Applications of biocalorimetry. London: Wiley; 1998. p. 267-275.
47. Garred P, Michaelsen TE, Aase A. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 1989;30:379-382.
48. Voice JK, Lachmann PJ. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur J Immunol 1997;27:2514-2523.
49. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991;9:457-492.
50. Ravetch JV. Fc receptors. Curr Opin Immunol 1997;9:121-125.
51. Daeron M. Fc receptor biology. Annu Rev Immunol 1997;15:203-234.
52. Ravetch JV. Fc receptors: rubor redux. Cell 1994;78:553-560.
53. 2, CD11b/CD18) and FcγRIII cooperate in generation of a neutrophil respiratory burst - requirement for FcγRII and tyrosine phosphorylation. J Cell Biol 1994;125:1407-1416.
54. Pound JD, Walker MR. Membrane receptors for the IgG subclasses. In: Shakib F, ed. The human IgG subclasses. Molecular analysis of structure, function and regulation. Oxford: Pergamon Press: 1990. p. 111-133.
55. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high affinity Fc receptor on IgG. Nature 1988;332:563-564.
56. Canfield SM, Morrison SL. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med 1991;173:1483-1491.
57. Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R. Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcγ receptor. Mol Immunol 1992;29:633-639.
58. Lund J, et al. Multiple binding sites on the CH2 domain of IgG for mouse FcγRII. Mol Immunol 1992;29:53-59.
59. Anderson CL, Ryan DH, Looney RJ, Leary PC. Structural polymorphism of the human monocyte 40 kilodalton Fc receptor for IgG. J Immunol 1987;138:2254-2256.
60. Gosselin EJ, Brown MF, Anderson CL, Zipf TF, Guyre PM. The monoclonal antibody 41H16 detects the leu-4 responder form of human FcγRII. J Immunol 1990;144:1817-1822.
61. Sarmay G, Jefferis R, Klein E, Benczur M, Gergely J. Mapping the functional topography of Fcγ with monoclonal antibodies - localization of epitopes interacting with the binding sites of Fc receptor on human K cells. Eur J Immunol 1985;15:1037-1042.
62. Kumpel BM, Rademacher TW, Rook GAW, Williams PJ, Wilson IBH. Galactosylation of human IgG anti-D produced by EBV-transformed B lymphoblastoid cell lines is dependent on culture method and affects Fc receptor mediated functional activity. Hum Antibodies Hybridomas 1994;5: 143-151.
63. Horwitz AH, Chang CP, Better M, Hellstrom KE, Robinson RR. Secretion of functional antibody and Fab fragment from yeast cells. Proc Natl Acad Sci USA 1988;85:8678-8682.
64. Kukuruzinska MA, Bergh MLE, Jackson BJ. Protein glycosylation in yeast. Annu Rev Biochem 1987;56:915-930.
65. Wright A, Morrison SL. Effect of altered CH2 associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994;180:1087-1096.
66. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature 1989;337:184-187.
67. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 1996;12:181-220.
68. Story CM, Mikulska JE, Simister NE. A major histocompatibility complex class I-like Fc receptor cloned from human placenta - possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 1994;180:2377-2381.
69. Kristoffersen EK, Matre R. Colocalization of the neonatal Fcy receptor and IgG in human placental term syncytiotrophoblasts. Eur J Immunol 1996;26:1668-1671.
70. Williams PJ, et al. Short communication. Selective placental transport of maternal IgG to the fetus. Placenta 1995;16:749-756.
71. Kibe T, et al. Glycosylation and placental transport of immunoglobulin G. J Clin Biochem Nutr 1996;21:57-63.
72. 2 microglobulin: possible protective role of FcRn. Immunology 1996;89:573-578.
73. 2 microglobulin-deficient mice. Eur J Immunol 1996;26:690-696.
74. 2 microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996;93:5512-5516.
75. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997;18:592-598.
76. Ghetie V, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997;15:637-640.
77. Brambell FWR, Hemmings WA, Morris IG. A theoretical model of gammaglobulin catabolism. Nature 1964;203:1352-1355.
78. Spiegelberg HL, Fishkin BG. The catabolism of human G immunoglobulins of different heavy chain subclasses. 3. The catabolism of heavy chain disease proteins and of Fc fragments of myeloma proteins. Clin Exp Immunol 1972;10:599-607.
79. Wawrzynczak EJ, Denham S, Parnell GD, Cumber AJ, Jones PT, Winter G. Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting C1q and high affinity Fc receptor binding have identical serum half-lives in the Balb/c mouse. Mol Immunol 1992;29:221-227.
80. Kim JK, Tsen MF, Ghetie V, Ward ES. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol 1994;24:542-548.
81. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988;332:738-740.
82. H2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRII binding. Immunology 1995;86:319-324.
83. Dorai H, Mueller BM, Reisfeld RA, Gillies SD. Aglycosylated chimeric mouse human IgG1 antibody retains some effector function. Hybridoma 1991;10:211-217.
84. Nose M, Leanderson T. Substitution of asparagine-324 with aspartic-acid in the Fc portion of mouse antibodies reduces their capacity for C1q binding. Eur J Immunol 1989;19:2179-2181.
85. Nose M, Heyman B. Inhibition of processing of asparagine-linked carbohydrate chains on IgG2a by using swainsonine has no influence upon antibody effector functions in vitro. J Immunol 1990;145:910-914.
86. Mageed RA, Borretzen M, Moyes SP, Thompson KM, Natvig JB. Rheumatoid factor autoantibodies in health and disease. Ann N Y Acad Sci 1997;815:296-311.
87. Jefferis R. Rheumatoid factors, B cells and immunoglobulin genes. Br Med Bull 1995;51:312-331.
88. Jefferis R, Iskandar M, Jaafar N, Steinitz M. Immunogenic and antigenic epitopes of immunoglobulins. 8. A human monoclonal rheumatoid factor having specificity for a discontinuous epitope determined by histidine arginine interchange as residue-435 of immunoglobulin G. Immunol Lett 1984;7:191-194.
89. Boyle MDP, ed. Bacterial immunoglobulin binding proteins. Vol 1. Microbiology, chemistry and biology. New York: Academic Press; 1990.
90. Johansson PJH, Ota T, Tsuchiya N, Malone CC, Williams RC. Studies of protein A and Herpes simplex virus 1 induced Fcγ-binding specificities - different binding patterns for IgG3 from Caucasian and oriental subjects. Immunology 1994;83:631-638.
91. Leatherbarrow RJ, Dwek RA. The effect of aglycosylation on the binding of mouse IgG to staphylococcal protein A. FEBS Lett 1983;164:227-230.
92. Nose M, Wigzell H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc Nath Acad Sci USA 1983;80:6632-6636.
93. Kato K, et al. Model for the complex between protein G and an antibody Fc fragment in solution. Structure 1995;3:79-85.